Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYME: Metformin + Myocet + Cyclophosphamide in HER2- Metastatic Breast Cancer
NCT01885013Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2010
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in breast cancer (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Progression-Free Survival at 42 months. Started Sep 2010; status: completed.
02
Drugs
metformin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01885013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885013.